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Abstract 
Hypoxia is a common feature in solid tumours. In glioma, it is considered the major driving force for 
tumour angiogenesis and correlates with enhanced resistance to conventional therapies, increased 
invasiveness and a poor prognosis for patients. Here we describe, for the first time, that miR675-5p, 
embedded in hypoxia-induced long non-coding RNA H19, plays a mandatory role in establishing a 
hypoxic response and in promoting hypoxia-mediated angiogenesis. We demonstrated, in vitro and in 
vivo, that miR675-5p over expression in normoxia is sufficient to induce a hypoxic moreover, 
miR675-5p depletion in low oxygen conditions, drastically abolishes hypoxic responses including 
angiogenesis. In addition, our data indicate an interaction of miR675-5p, HIF-1α mRNA and the RNA 
Binding Protein HuR in hypoxia-induced responses. We suggest the modulation of miR675-5p as a new 
therapeutic option to promote or abolish hypoxia induced angiogenesis. 
Key words: Angiogenesis, hypoxia, glioma, miRNA675, optical imaging, HuR, VHL. 
Introduction 
Hypoxia is a common feature in solid tumours 
and plays a key role in many aspects of tumour 
growth and development as well as in therapeutic 
response. Phenotypic changes, fundamental to 
malignant progression, are mediated by cellular 
hypoxia that, through the activation of several 
molecular cascades, induces genomic instability, loss 
of apoptotic potential, angiogenesis, resulting in an 
increase of metastasis and, finally, radio- or 
chemo-therapy resistance [1]. During malignant 
progression, the formation of hypoxic areas, within 
the expanding mass of a solid tumour, induces the 
so-called angiogenic switch, characterized by the 
stimulation of vessel growth [2, 3]. 
In glioma, hypoxia is considered the major 
driving force for tumour angiogenesis [4] and the 
Hypoxia Inducible Factor (HIF-1α) is the critical 
player in the establishment of vascular supply [5]. In 
normoxic conditions, HIF-1α is hydroxylated on 
proline residues (Pro402 and Pro564) by soluble Prolyl 
Hydroxylases (PHD), and targeted for rapid 
proteasomal degradation by the von Hippel-Lindau 
(VHL) tumour suppressor, the substrate recognition 
component of an E3-ubiquitin ligase. Loss of pVHL 
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function results in HIF-1α stabilization, increase of its 
transcriptional activity and subsequent up-regulation 
of HIF-1α target genes [6]. During hypoxia, 
prolyl-hydroxylation is prevented, thus allowing 
HIF-1α to escape proteolysis, dimerize with HIF-1β, 
and translocate to the nucleus where, it can directly 
promote neo-angiogenesis by inducing the expression 
of Vascular Endothelial Growth Factor (VEGF) [7, 8], 
the most powerful pro-angiogenic cytokine. Like 
VEGF, HIF-1α is able to activate a multitude of 
downstream genes involved in survival and 
proliferation (IGF-2, TGF-α, NOTCH-1), invasiveness 
(CXCR-4, MMP), new vessels formation (VEGF-A, 
VEGF-R1, ANGPT-1), metabolic adaptation 
(GLUT1/3, GAPDH) and pharmacological resistance 
[9] by binding Hypoxia Responsive Elements (HRE) 
in their enhancer and promoter regions [10].  
Among the genes that were found to be altered 
in hypoxia in response to HIF-1α up-regulation, the 
long non-coding RNA (lncRNA) H19 was 
over-expressed in several tumours. H19 is considered 
as an oncogenic lncRNA, positively correlated with 
breast cancer [11, 12], bladder cancer [13, 14] and 
cervical carcinomas [15]. Ectopic H19 expression is 
able to enhance the tumorigenic potential of 
hepatocellular carcinoma cells in vitro and in animal 
models [16] and, as we recently described, it can also 
act as angiogenic inducer [17]. H19 exon1 encodes for 
two conserved microRNAs, miR675-3p and 
miR675-5p, and it has been speculated that 
H19/miR-675 signalling axis plays an important role 
in carcinogenesis [18]. Recent studies have shown that 
miR675-5p expression is up-regulated in several 
cancer types such as glioma [19], gastric cancer [20, 
21], colorectal cancer [18], skeletal muscle tumours 
and hepatocellular cancer [22]. However, a low 
expression of miR675-5p has been found in adrenal 
cortical carcinoma and metastatic prostate cancer cells 
[23, 24], implying that miR675-5p may play different 
roles depending on the tumour type. To our 
knowledge, no data have been reported up to date 
about the role of H19’s miRNAs during hypoxia.  
Here, we reveal a fundamental role of 
hypoxia-induced H19 and specifically of the 
H19-embedded miR675-5p that is required to sustain 
hypoxic responses, driving glioma angiogenesis and 
affecting endothelium. We demonstrated that the 
down-regulation of miR675-5p, in low O2 partial 
pressure conditions, inhibits the hypoxic response by 
decreasing the nuclear HIF-1α and its mRNA. 
Moreover, our data indicate an involvement of the 
RNA binding protein HuR, which if bound to HIF-1α 
and VEGF mRNAs under hypoxic condition, was 
deregulated after miR675-5p depletion. In addition, 
miR-675-5p over expression in normoxia is able, per se, 
to promote hypoxic responses by driving HIF-1α 
nuclear accumulation and reducing VHL gene 
expression. 
Finally, by combining in vivo administration of 
either the miR675-5p mimic or miR675-5p inhibitor 
and optical molecular imaging techniques in a 
preclinical glioma model, we identified miRNA675-5p 
as a new therapeutic target for glioma treatment. 
Results 
Validation of suitable cellular models for 
hypoxia studies 
In order to preliminarily investigate the effects of 
hypoxia in vitro on critical cytotypes involved in 
glioblastoma progression, we used two widely 
accepted cellular models: the glioblastoma cell line 
U251 and Human Umbilical Vein Endothelial cells 
(HUVECs). The hypoxia responsiveness of both cell 
types was tested after incubation for six hours in a 
hypoxic chamber with 1% O2 atmosphere. ELISA 
(figure 1A) and immunocytochemistry (figure S1) 
results show that both glioblastoma and endothelial 
cells respond to hypoxia by increasing HIF-1α nuclear 
levels. To functionally assess HIF-1α activity, the 
transcription of its target genes, involved in 
angiogenesis and metabolic changes, has been 
assessed by Real time-PCR analysis. As shown in 
figure 1B, HIF-1α up-regulation correlates with 
increased mRNA levels of its target genes involved in 
i) metabolic switch (GAPDH), ii) angiogenesis (VEGF) 
and iii) invasion and metastasis (CXCR-4, SNAIL, 
SLUG) whereas, other hypoxia-related genes (i.e. 
CAV-1 and Integrin-1), were not modulated. In 
addition, levels of soluble VEGF, the main driver of 
angiogenesis, were analysed by ELISA (figure 1C). 
Both cell lines increased VEGF secretion under 
hypoxia conditions, thus confirming that our cellular 
models respond to low oxygen conditions and 
therefore provide a suitable model for our study. 
The long non-coding RNA H19 [25], well 
documented to be involved in cancer progression and 
metastasis [16], has been shown to be up-regulated 
under hypoxia conditions. Although it is known that 
lncRNA H19 contains two different miRNA 
(miRNA675-3p and miRNA675-5p), their individual 
role in hypoxia has not been described in literature. 
As expected, under hypoxic conditions, a ten-fold and 
five-fold increase in H19 transcription level was 
detected in both cell models (in U251 and HUVECs, 
respectively) (figure 1D, left panel). Notably, only 
miRNA675-5p was overexpressed in both cell lines in 
hypoxic conditions, while no changes were observed 
for miRNA-675-3p levels (figure 1D, right panel). 
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Figure 1: U251 glioma cells and HUVEC endothelial cells as suitable models for hypoxia studies. (A) ELISA assay for HIF-1α performed in U251 and HUVEC nuclear extracts 
after 6h of hypoxia. Data are expressed as Absorbance (ABS) values at 450nm. (B) Real-time PCR performed on U251 and HUVEC cells 6 hours post-hypoxia. Data were normalized for 
β-actin, and ∆∆ct is expressed as fold of induction (FOI) of analyzed genes in hypoxia vs normoxia. The dashed line indicates control sample in normoxia. (C) ELISA assay for VEGF levels in 
supernatants from both cell lines after 6 hours of hypoxia. Data are expressed as pg/ml of soluble VEGF. (D) Left panel: Real time-PCR for lncRNA H19, after 6h of hypoxia, normalized for 
β-actin. Data are expressed as FOI of hypoxia-treated cells compared to normoxia samples. Right panel: Real time-PCR for H19’s microRNAs, miR675-3p and miR675-5p, after 6h of 
hypoxia. Data were normalized for RNU48. Data are expressed as FOI compared to scramble-treated cells. Values are presented as the mean ± SD. Hypoxia vs normoxia * p<0.05; **p<0.01;* 
**p<0.001.  
 
The presence of the miRNA675-5p is required 
to induce hypoxia-mediated angiogenesis 
With the aim to investigate the role of this 
microRNA in cell response to hypoxia, we 
down-regulated miR675-5p levels in hypoxic 
conditions by transfecting both cell lines with a 
specific inhibitor. The inhibition of miRNA675-5p in 
hypoxic conditions correlated with a reduction of 
HIF-1α activity. Both in endothelial and glioma cell 
models, miRNA675-5p inhibitor induced a 
down-regulation of nuclear HIF-1α (figure 2A and 
figure S2), together with a reduction in the expression 
of its target genes (figure 2B). Concerning 
hypoxia-induced angiogenesis, VEGF mRNA (figure 
2B) and protein (figure 2C) were strongly 
down-regulated in presence of miRNA inhibitor, both 
in U251 and HUVEC cells.  
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Figure 2: Gain and loss of function suggests a critical role of miR675-5p on hypoxia modulation. (A) ELISA for HIF-1α nuclear level in U251 and HUVECs transfected with 
miR675-5p inhibitor and exposed to hypoxia for 6h. Data are expressed as ABS values at 450nm. (B) Real-time PCR from U251 and HUVECs exposed to hypoxia after miR675-5p inhibitor 
or scramble control transfection. Data were normalized for β-actin and ∆∆ct is expressed as fold of induction (FOI) of indicated genes after inhibitor transfection compared to scramble 
control (dashed line). (C) ELISA assay for VEGF level in supernatant from both cell lines transfected with miRNA inhibitor or negative control and exposed to hypoxia for 6h. Data are 
expressed as pg/ml of soluble VEGF. Values are presented as the mean ± SD. Inhibitor vs scramble * p<0.05; **p<0.0; ***p<0.001. (D) HIF-1α nuclear level analyzed by ELISA assay in U251 
and HUVEC cells after 18h of miR675-5p mimic transfection in normoxia. Data are expressed as ABS values at 450nm. (E) Real-time PCR performed on U251 and HUVEC cells after 
miR675-5p mimic-transfection. Data were normalized for β-actin, and ∆∆ct is expressed as fold of induction (FOI) in cells transfected with mimic compared to control (dashed line). (F) ELISA 
assay for VEGF level in supernatant from both cell lines 18h after mimic transfection. Data are expressed as pg/ml of soluble VEGF. Values are presented as the mean ± SD. Mimic vs scramble 
* p<0.05; **p<0.01;***p<0.001. 
 
No differences were found in cell viability in 
hypoxia with or without miR675-5p inhibitor (figure 
S3). In order to further investigate the role of 
miRNA675-5p, cells were also analysed in normoxic 
conditions overexpressing miRNA675-5p. As shown 
in figure 2D and figure S2, the presence of 
miRNA675-5p was sufficient to promote a significant 
HIF-1α nuclear translocation in normoxic conditions. 
Real time-PCR results confirmed that nuclear HIF-1α 
induced the transcription of its target genes also in 
normoxic conditions (figure 2E). Similarly, 
transfection with miRNA675-5p mimic in normoxia 
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was able to induce, in both cell lines, VEGF secretion 
as measured by ELISA (figure 2F). Tube formation 
assay in Figure S4 showed a significant decrease in 
the number and the length of tubular-like structures 
when HUVECs were treated in hypoxia with 
miRNA675-5p inhibitor. Conversely, when HUVECs 
were treated in normoxia with miRNA675-5p mimic, 
an increase of tubular-like structures was detected, 
confirming a functional involvement of this miRNA in 
the angiogenic process.  
MiRNA675-5p drives hypoxic responses in vivo 
In order to determine if the presence or depletion 
of miRNA675-5p causes in vivo the same effect 
observed in vitro, a glioma orthotropic murine model 
was generated by stereotaxic surgery injection of 
U251-HRE-mCherry cells. In these cells, Luciferase 
expression controlled by HRE sequences, allows the 
evaluation of hypoxia levels over time, while the 
tumour growth can be evaluated by mCherry 
fluorescence assessment at the same experimental 
points. Before in vivo injection, U251-HRE-mCherry 
cells were tested in vitro (figure 3A), and showed an 
increase of Luciferase activity after transfection with 
miRNA675-5p mimic compared to control plasmid. 
The time line in the material and methods section 
describes the procedure for the in vivo treatment. 
Briefly: starting twelve days post U251-HRE-mCherry 
cell injection, mice underwent four intravenous 
administration of miRNA675-5p mimic or scramble as 
negative control. As previously demonstrated by Lo 
Dico et al [26] and confirmed in our control mice, 
eighteen days after glioma cells injection, a strong 
increase of hypoxia can be detected in vivo by using 
optical imaging techniques (figure 3B, left panel). 
The administration of MiRNA675-5p mimic starting 
from day 12, before the establishment of hypoxia, 
anticipated hypoxia induction at day 15 and enforced 
this as indicated in figure 3B. ROI analyses confirmed 
the results with a statistically significant difference in 
luciferase emission at day 19 in the mimic-treated 
group compared to control (figure 3B, right panel). 
Subsequently, both groups were analysed for HIF-1α 
downstream target and neo-angiogenesis biomarker 
expression through the use of two different 
fluorescent probes, targeting CAIX and Integrin α5β3, 
respectively (figure 3C, left panel). HypoxiSense 
acquisition showed the induction of CAIX expression 
in mimic-treated mice, in agreement with an increase 
in HIF-1α activity. At the same time, IntegriSense 
probe showed an increase in Integrin α5β3 expression 
correlated to the neo-angiogenesis stimulation. Image 
quantification confirmed the results observed in 
fluorescence images (figure 3C, right panel). 
Finally, tumour growth rate was analysed by 
evaluation of mCherry signal. Systemically 
administered miRNA675-5p mimic enhanced tumour 
growth, as demonstrated by the higher mCherry 
signal of the treated- group compared to the control 
group at the end-point (figure 3D). This is in 
agreement with the longitudinal study, where an 
induction of tumour growth was observed over time 
in the mimic-treated group (Figure S5) and confirmed 
by the assessment of tumour weight at ex vivo 
examination (Figure S6). These data suggest a role for 
miRNA675-5p in the earlier establishment of the cell 
response to hypoxia that correlates with the earlier 
neo-angiogenesis induction and higher tumour 
growth. To further demonstrate the role of 
miRNA675-5p in glioblastoma progression, 
miRNA675-5p inhibitor was administered starting 
from day 21 post glioma cell injection, when hypoxia 
was already established, following the scheduling in 
materials and methods. Figure 4A (Left panel) 
showed that, by abolishing miRNA675-5p levels, 
HypoxiSense and IntegriSense specific signals were 
significantly reduced at the end of the treatment. 
These results were also confirmed by ROI analysis 
(figure 4A, right panel). As regards to tumour growth 
kinetic, at the end point, we observed a smaller 
tumour mass in the animal group treated with 
miRNA675-5p inhibitor compared to the control 
group and this reduction was already present after the 
second miRNA675-5p inhibitor administration 
(Figure S7). These results were confirmed by ex vivo 
tumour weight evaluation showing that in 
inhibitor-treated animals, tumours were characterized 
by a lower weight (Figure S6) compared to tumours 
from the control groups (both vehicle and scramble 
groups). Ex vivo IHC confirmed the impairing of 
HIF-1α nuclear translocation after miRNA675-5p 
inhibitor administration (Fig.4C). All in vivo data were 
supported by H&E and IHC analysis (Figure S8) 
Overall, our data indicate that the inhibition of 
miRNA675-5p in vivo is able i) to turn off tumour 
molecular response to hypoxia ii) to constrain 
angiogenesis and iii) to block hypoxia-mediated 
tumour growth, thus suggesting a therapeutic role for 
miRNA675-5p inhibitor in glioblastoma. 
Study of miRNA675-5p putative target and 
molecular mechanism 
In order to investigate the molecular mechanism 
driving miRNA675-5p effects, we focused our 
attention on VHL, a physiological HIF-1α inhibitor, 
indicated by the miRbase database [27] as putative 
target for miRNA675-5p. Moreover, it is well known 
that the loss of VHL, in normoxia, is sufficient not 
only to stabilize HIF-1α subunits, but also to fully 
activate HIF-1α-mediated responses [6]. In order to 
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validate VHL as miRNA target in our experimental 
model, we transfected U251 cells with different doses 
of miRNA675-5p mimic. As indicated in figure 5A, 
miRNA transfection induced a dose-dependent 
reduction in VHL mRNA, while the western blot 
(figure 5B) revealed a reduction in pVHL already 
occurring after the administration of 5pmoli of 
miR675-5p mimic. However, luciferase reporter 
system showed that miR675-5p does not target the 
VHL gene directly (figure 5C) as observed for 
miR21-5p [28] that has VHL as direct target. Overall, 
our data suggest that miR675-5p is able to affect VHL 
expression indirectly.  
 
Figure 3: miR675-5p in vivo is able to enhance hypoxia establishment and neo-angiogenesis. (A) Luciferase in vitro assay performed on U251-HRE lysated cells after 18h of 
miR675-5p mimic-transfection. Data are represented as RLU (luminescent counts normalized to protein content) of mimic-treated cells compared to scramble-treated cells. Mimic vs scramble 
***p<0.001. (B) Left panel: Representative (n=5) 2D bioluminescent (rainbow scale) of U251-HRE-mCherry tumours in scramble and miR675-5p mimic-treated mice (one of 5 mice) at day 
12 (pre-treatment), day 15 (after two doses) and day 19 (end of treatment). Images are presented with the same scale bar. Right panel: Graphical representation of Luciferase activity over 
time during treatment. Data are presented as average radiance (photons/s/cm^2/steradian). (C) Left panel: Representative 2D images of mice co-injected with HypoxiSense 680 (BlueHot 
scale) and IntegriSense 750 (YellowHot scale) and axial images of IntegriSense750 co-registered with CT scan. All scans were performed at the final time point (day 19). Right panel: 
Quantification of HypoxiSense680 and IntegriSense750 fluorescence by ROI analysis for scramble and mimic-treated mice. Data are expressed as average radiance efficiency 
[(photons/s/cm^2/steradian)/(μW/cm^2)]. (D) Left panel: Representative (n=5) 2D mCherry fluorescent signal (rainbow scale) of U251-HRE-mCherry tumours in scramble and miR675-5p 
mimic-treated mice at day 19. Right panel: Graphical representation of mCherry activity at the end of treatment. Data are presented as average radiance efficiency 
[(photons/s/cm^2/steradian)/(μW/cm^2). Images are presented with the same scale bar. Mimic-treated mice vs scramble- treated mice * p<0.05; **p<0.01; ***p<0.001. 
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Figure 4: miR675-5p inhibitor counteracts hypoxia-mediated angiogenesis in vivo. (A) Left Panel: Representative (n=5) 2D images of scramble or miR675-5p inhibitor-treated 
mice co-injected with HypoxiSense 680 (BlueHot scale) and IntegriSense 750 (YellowHot scale) and axial images of IntegriSense750 co registered with CT scan. All scans were performed at 
the final time point (day 28). Right panel: Quantification of HypoxiSense 680 and IntegriSense 750 fluorescence by ROI analysis for scramble and miR675-5p inhibitor-treated mice 
(considering five mice for each treatment). Data are expressed as average radiance efficiency [(photons/s/cm^2/steradian)/(μW/cm^2)]. (B) Left Panel: Representative (n=5) 2D mCherry 
fluorescent signal (rainbow scale) of U251-HRE-mCherry tumours in scramble and inhibitor-treated mice (one of five mouse for each treatment) at day 28. Images are presented with the same 
scale bar. Right panel: Graphical representation of mCherry activity at the end of treatment considering five mice for each treatment. Data are presented as the average radiance efficiency 
[(photons/s/cm^2/steradian)/(μW/cm^2). Images are presented with the same scale bar. Inhibitor-treated mice vs scramble-treated mice * p<0.05; **p<0.01; ***p<0.001. (C) 
Immunoistochemistry for HIF-1α staining in scramble and miR675-inhibitor-treated group (scale bar is represented). 
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Figure 5: miR675-5p regulates HIF-1α mRNA stability by VHL/HuR axis. (A) Real-time PCR for VHL was done on U251 cells 18h after transfection with 5pM, 15pM, 30pM and 
60pM of miR675-5p mimic. The dashed line indicates the control sample (scramble-treated). Values are presented as the mean ± SD. Mimic vs scramble * p<0.05; **p<0.01. (B) Western Blot 
for VHL and β-actin from U251 cells transfected with miR675-5p mimic (5pM) or scramble negative control. (C) Expression of VHL-regulated miRNA was validated by Luminescence assay 
kit, a secondary reporter was used for transfection normalization. Data are expressed as Relative Luciferase Activity in pGL3-pVHL-WT construct transfected with miR675-5p or miR21-5p 
and their relative scrambles. pGL3-control is represented as dashed line. The mean ± SD of three independent experiment is shown, and each sample was assayed in triplicate. (D) Left panel: 
Real-time PCR for HIF-1α performed on U251 and HUVEC cells 6 hours post-hypoxia. Data were normalized for β-actin, and ΔΔCt is expressed as fold of induction (FOI) of HIF-1α in hypoxia 
vs normoxia. Right panel: Real-time PCR performed on U251 and HUVEC cells 6 hours post-hypoxia and after miRNA675-5p inhibitor transfection. Data were normalized for β-actin, and 
ΔΔCt is expressed as fold of induction (FOI) of HIF-1α in hypoxia in inhibitor vs normoxia. (E) Left panel: Western Blot for HuR and β-actin from U251 cells transfected with miR675-5p 
inhibitor (5pM) or scramble negative control after 6h of hypoxia. Right panel: RNA-immunoprecipitation for HuR. Real time PCR for VEGF and HIF-1α were performed starting from HuR 
co-immunoprecipitated RNA in different culture conditions. Ct value was normalized to the Input RNA Ct value. Data are expressed as fold enrichment above the input percentage and 
presented as the mean ± SD. Inhibitor vs scramble negative control ***p<0.001. (F) Molecular mechanism of miRNA 675-5p in hypoxia condition. The dashed line indicates our experimental 
results. 
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Concerning the down-regulation of nuclear 
HIF-1α induced by miRNA675-5p depletion in 
hypoxia, our data demonstrated that neither VHL 
neither proteasome inhibition were able to rescue 
nuclear HIF-1α levels (figure S9). Therefore, we 
focused our attention on HIF-1α mRNA. The real time 
PCR in figure 5D indicated that while hypoxia 
induced an up-regulation of HIF-1α transcript, 
miRNA675-5p inhibitor treatment strongly inhibited 
HIF-1α mRNA transcription. These data let us to 
suppose a transcript destabilization. For this reason, 
we focused our attention on the RNA binding protein 
HuR, which has been already demonstrated to 
stabilize HIF-1α and VEGF mRNAs in low O2 partial 
pressure [29, 30]. While no changes in HuR protein 
levels were detected after miRNA675-5p inhibition in 
hypoxia (figure 5E, left panel), notably, RIP 
experiments on the amount of HIF-1α and VEGF 
mRNAs bound to HuR gave an interesting insight. As 
shown in figure 5E (right panel), levels of HIF-1α and 
VEGF mRNAs were found significantly decreased 
when hypoxic U251 cells were treated with 
miRNA675-5p inhibitor. VEGF and HIF-1α mRNAs 
were not amplified from the control IgG 
immunoprecipitation (data not shown). 
Discussion 
Hypoxia is an essential feature of the neoplastic 
microenvironment, regulating angiogenesis through 
multiple pathways, including VEGF signalling [31]. 
Since the inhibition of angiogenesis in tumorigenesis 
impairs tumour progression [32], the significance of 
hypoxia-mediated angiogenesis in driving tumour 
growth is receiving increased attention. The master 
gene involved in cell molecular response to hypoxia, 
HIF-1α, regulates the expression of multiple 
angiogenic factors. Therefore, targeting HIF-1α for 
therapy may result in a more comprehensive outcome 
than the one achieved by any single anti-angiogenic 
factor [33, 34]. 
Hypoxia is a predominant feature in glioma and 
its microenvironment [35], it is associated with 
tumour growth, progression and resistance to 
conventional therapy [36]. To better understand the 
role of hypoxia in glioma establishment and 
progression, we investigated how U251 glioma cells 
and an endothelial cell model could react to hypoxic 
stimuli. Once our experimental models were 
validated as suitable for hypoxia studies, we 
investigated tumorigenesis. Recently, we and others 
have shown that the long non-coding RNA H19 could 
promote cancer development [16, 17, 37] and Matouk 
et al have already demonstrated that this oncogenic 
activity of lncRNA H19 is enhanced under hypoxic 
stress [16, 25]. Interestingly, recent studies suggest a 
role of H19 in glioma establishment and progression 
[38]. Moreover, Shi et al. have showed that H19 and 
its encoded miRNA675 were positively correlated 
with glioma grade suggesting a critical role for 
miRNA675 in tumour malignancy/severity and a 
possible use as prognostic marker [19]. However, two 
different miRNA are embedded in H19 and indicated 
as miR675. Our results showed, for the first time to 
our knowledge, that hypoxia promotes, together with 
lncRNA H19, the expression of miRNA675-5p only 
while no modulation was found for the other miRNA 
embedded in H19, miRNA 675-3p. MicroRNAs are a 
new class of master regulators that control gene 
expression and are responsible for many normal and 
pathological cellular processes. Several miRNAs, 
indicated as Hypoxia-Regulated MicroRNAs (HRMs), 
have already been associated to the hypoxic response. 
These non-coding RNAs are induced by HIF-1α 
through direct or indirect activation and cooperate 
with it by promoting hypoxic response through the 
down-regulation of normoxic-genes [39]. 
Interestingly, the vast majority of hypoxia-induced 
microRNAs are also overexpressed in a variety of 
human tumours [40]. In literature, the involvement of 
miR675-5p in tumorigenesis is still controversial, in 
fact, while it has been indicated as anti-tumoral in 
small cell lung cancer and prostate cancer [23] [41] it 
was described as a pro-tumoral molecule in human 
colorectal and breast cancer [5, 42]. We demonstrated 
that miR675-5p is a hypoxia-regulated microRNA 
able, by itself, to mimic a low oxygen condition in 
normoxia; indeed it was found i) essential for hypoxia 
establishment, ii) a stimulator of hypoxia-mediated 
angiogenesis and iii) a promoter of glioma 
progression. On the other hand, by counteracting 
tumoral hypoxia-induced events, it may have an 
important role in therapeutic approaches. In our 
system, we demonstrated that by abrogating 
miR675-5p function in hypoxia, HIF-1α activity was 
completely abolished. This effect reflected also in the 
down-regulation of hypoxia targets expression and in 
the negative modulation of angiogenesis, indicating, 
for the first time, a critical role for miR675-5p in these 
processes ad suggesting it as a therapeutic agent. 
MicroRNAs are pleiotropic modulators, able to 
regulate simultaneously several target genes and in 
the case of hypoxia-regulated microRNAs, each HRM 
is predicted to downregulate more than 10 genes, 
sometimes as many as 200 [39]. Considering the 
effects on HIF-1α regulation and the data from 
miRbase interrogation, among the miR675-5p 
predicted targets, we focused our attention on pVHL, 
which targets HIF-1α for proteosomal degradation 
[43] and whose inhibition in normoxia is sufficient to 
promote the expression of VEGF [44]. As indicated by 
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Mack et al. [6], loss of Vhl is sufficient to completely 
dysregulate HIF-1α and to promote its activity. 
Interestingly, while these authors indicated that VHL 
deletion did not enhance the growth in subcutaneous 
tumours derived from primary cells Vhl-/-, in our in 
vivo experiments miR675-5p administration and, 
subsequently, VHL down-modulation, promote 
tumour growth. This effect could be ascribable to the 
dual action of the miRNA on glioblastoma cells as 
well as on endothelial cells that, as indicated by our in 
vitro experiments, respond to miRNA-675 over 
expression. However, the involvement, in this process 
of other miR675-5p targets that could reinforce the 
activity of hypoxia in tumour progression appears 
conceivable.  
When low oxygen induces the expression of 
HRMs, some genes targeted by these miRNAs 
stabilize HIF1-α by forming positive-feedback loops: 
miR-210 could repress glycerol-3-phosphate 
dehydrogenase 1-like (GPD1L), which, in turn, affects 
HIF1α stability or miR-424 that, by suppressing 
cullin2 in human endothelial cells, blocks HIF1α 
ubiquitination [45].  
In our in vitro and in vivo models the abrogation 
of miR675-5p expression, although in low oxygen 
condition, was able to affect both HIF-1α activity and 
synthesis, thus turning off hypoxic responses, 
including angiogenesis. The treatment with 
miR675-5p inhibitor in low oxygen, while did not 
modulate VHL, eliminated the principal regulator of 
hypoxia-responsive pathway through the 
destabilization of HIF-1α mRNA. Taking these results 
into account, with the hypothesis of the involvement 
of different partners, and since it has been 
demonstrated that the RNA binding protein HuR, 
binds both HIF-1α [29] and VEGF [30] mRNAs 
increasing their stability, we demonstrated for the 
first time that the expression of miR675-5p during 
hypoxia plays a fundamental role in sustaining this 
mRNA stabilization. Our data, exemplified in figure 
5F, are in line with recent studies [46, 47] describing 
the interaction between RNA Binding Proteins and 
miRNA in post-transcriptional gene regulatory 
mechanisms. Further studies are required to clarify 
the interaction between miR675-5p and HuR. In 
conclusion, in this study we unveiled a key role of 
miR675-5p in hypoxia where its function is 
mandatory to support the process, and we identified 
in miR675-5p a new therapeutic target in tumour 
progression, where miRNA675-5p inhibition is able to 
counteract hypoxia process. On the other hand, we 
demonstrated that miR675-5p could drive 
angiogenesis, by mimicking hypoxia in a non-hypoxic 
microenvironment, thus suggesting a novel 
therapeutic option for angiogenesis promotion. 
Materials and Methods 
Cell culture and reagents 
U251 glioma cells were routinely maintained in 
RPMI supplemented with 10% heat-inactivated foetal 
bovine serum, penicillin and streptomycin (50 
IU/ml), 2 mM glutamine (Euroclone, UK). HUVECs 
(C2519A Lonza, Belgium) were grown in endothelial 
growth medium (EGM, bullet kit, Lonza, Belgium) 
according to the supplier’s instructions. Cells were 
maintained in a humidified atmosphere of 5 % of CO2 
at 37 °C. During hypoxia experiments, both U251 and 
HUVEC cells were seeded at 10,000 cells/cm2 and 
incubated in a "Hypoxic Chamber" [48] containing 1% 
O2 gas mixture for 6 hours (h).  
To obtain biochemical VHL inactivation, cells 
were treated with 100 μM of the hypoxia mimetic 
agent deferoxamine (DFX, Sigma-Aldrich, St. Louis, 
MO, USA) for 6 hours before miRNA675-5p inhibitor 
transfection. DFX was resuspended in distilled sterile 
water. The proteasome inhibitor MG132 (Calbiochem, 
San Diego, CA) was dissolved in DMSO solution 
buffer at 10 mM as a stock solution and cells were 
treated for 24 hours. DMSO was used as a control 
vehicle. 
Cell transfection 
For cell transfection, Attractene Transfection 
Reagent (cat.number 1051531, Qiagen) was used 
following the manufacturer’s indication. Briefly, U251 
and HUVEC cells were seeded at 10,000 cells/cm2 and 
transfected with 15pmoles/ml of hsa-mir675-5p 
inhibitor (cat.number 4464084, Life Technologies, 
Italy), hsa-mir675-5p mimic (cat.number 4464066, Life 
Technologies) or scrambled negative control (cat. 
number 4464058, Life Technologies). Eighteen hours 
after transfection, the medium was collected and the 
cells processed for the following assays. 
TransAM Kit 
An ELISA-based kit (TransAM Kit, 
Vinci-Biochem, Italy) was used to detect and quantify 
HIF-1α transcriptional factor activity following the 
manufacturer’s instructions. Briefly, nuclear extracts 
were firstly prepared using the Nuclear Extract Kit 
(Vinci-Biochem) and 8µg of the samples were added 
to the coated plate and analysed at 450nm with Gen5 
Microplate Collection & Analysis Software Data 
(BioTek Instruments, Inc.®). Data were expressed as 
HIF-1α protein content in the total nuclear extract 
(Absorbance). 
ELISA assay 
VEGF concentration was quantiﬁed using an 
ELISA kit (VEGF Human ELISA KitNovex® 
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cat.number KHG011, Life Technologies) according to 
the manufacturer’s protocol. U251 or HUVEC- 
conditioned medium was collected after hypoxia 
treatment or transfection with miR675-5p inhibitor or 
mimic. Data were expressed as VEGF concentration in 
pg/ml.  
Immunocytochemistry 
Immunocytochemistry was performed on PFA 
4% fixed cells, and stained with anti-HIF1α 1/100 
(HIF-1 alpha Antibody, NB100-105, Novus 
Biologicals), while the secondary antibody was 
Alexa-Fluor 488 from Molecular Probes. The nuclei 
were stained with Hoechst, and preparations were 
analyzed by confocal microscopy (Nikon A1 Confocal 
Laser Microscope).  
RNA extraction and Real-time PCR 
RNA was extracted using the commercially 
available illustraRNAspin Mini Isolation Kit (GE 
Healthcare, Italy), according to the manufacturer’s 
instructions. Total RNA was reverse-transcribed to 
cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystem, USA). 
Real-time PCR was performed in duplicates for each 
data point, and oligonucleotides used are described in 
table 1. 
Changes in the target mRNA content relative to 
an housekeeping gene (β-actin) were determined with 
the ∆∆ct Method. For miRNA expression, 250 ng of 
RNA were reverse transcripted according to the 
manufacturer’s instructions (cat.number 4366596, 
TaqManMicroRNA Reverse Transcription, Applied 
Biosystem). Taqman probes were used to analyse: 
miR675-5p (cat.number 4440887,Applied Biosystem), 
miR 675-3p (cat.number 4427975, Applied Biosystem), 
RNU48 (cat.number 4427975, Applied Biosystem), 
H19 (Hs00262142_g1 Life Technologies) and Integrin 
β-1 (HS_00559595, Applied Biosystem). Changes in 
the target miRNA content relative to housekeeping 
RNU48 were determined with the ΔΔct Method. 
Luminescence Assay Kit 
For the study of miR675-5p target, pGL3-control 
or pGL3-VHL-WT was transfected in U251 cells 
according to the manufacturer’s instructions. After 
24h, the medium was changed and the cells were 
treated for 18h with miR675-5p or miR21-5p and their 
relative scrambles. At the end of the treatment, the 
medium was collected and measured for Gaussia 
Luciferase (GLuc) and the transfection was 
normalized for the Secreted Alkaline Phosphatase 
(SEAP). Results were detected by Glomax 
(GloMax-Multi Detection System; Promega, Madison, 
WI, USA).). 
Endothelial tube formation assay 
HUVECs were seeded at 50,000 cells/well and 
transfection with miRNA mimic, inhibitor or scramble 
controls. They were then grown in growth 
factor-reduced Matrigel-coated 24 well plates and 
incubated up to 2 hours at 37°C (356234,BD Matrigel 
Matrix). Tube formation was examined under an 
inverted microscope and photographed at 20× 
magnification (Leica Microscopy). The length of the 
cables was measured manually with the IMAGE-J 
software (http://rsbweb.nih.gov/ij/). 
In Vivo Imaging Study Design 
Animal experiments were carried out in 
compliance with the institutional guidelines for the 
care and use of animals, which have been notified to 
the Italian Ministry of Health. 
U251-HRE human glioma cells (kindly provided 
by Dr. G. Melillo, National Cancer Institute, Frederick, 
MD, USA) express the luciferase reporter gene under 
the control of three copies of an HRE sequence 
(pGL2-Tk-HRE). This cell line was further stably 
transfected with pCLL-PGK-mCherry-WPRE 
lentivirus (kindly provided by Dr. S. Rivella, Weill 
Cornell Medical College, New York, NY, USA), 
containing the mCherry gene under the control of the 
constitutive promoter PGK.  
 
Table 1. Gene primers used to study gene expression profiling. 
Gene Forward primer Reverse primer 
VEGF CGAGGGCCTGGAGTGTGT CGCATAATCTGCATGGTGATG 
VEGFR1  CGGTCAACAAAGTCGGGAGA CAGTGCACCACAAAGACACG 
H19 GCACCTTGGACATCTGGAGT TTCTTTCCAGCCCTAGCTCA 
HIF-1α  TGATTGCATCTCCATCTCCTACC GACTCAAAGCGACAGATAACACG 
HIF-2 CTTTTCGGGTCTGACAGCCT TGTGTTCGCAGGAAGCTGAT 
CXCR4 TACACCGAGGAAATGGGCTCA AGATGATGGAGTAGATGGTGGG 
VHL 1 GACGGACAGCCTATTTTTGCC TCCCATCCGTTGATGTGCAA 
CAVEOLIN 1 AGACGAGCTGAGCGAGAAGC CCAGATGTGCAGGAAAGA 
SLUG CATGCCTGTCATACCACAAC GGTGTCAGATGGAGGAGGG 
SNAIL GCGAGCTGCAGGACTCTAAT CCCGCAATGGTCCACAAAAC 
GAPDH ATGGGGAAGGTGAAGGTCG GGGTCATTGATGGCAACAATATC 
B-ACTIN ATCAAGATCATTGCTCCTCCTGA CTGCTTGCTGATCCACATCTG 
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Before orthotropic injection, U251-HRE cells 
were tested for specific miRNA675-5p responsiveness. 
After 18h of miRNA675-5p mimic or scramble 
transfection, lysed cells were analyzed on a 
luminometer (GloMax-Multi Detection System; 
Promega, Madison, WI, USA). Data were normalized 
to milligram of proteins measured by Bradford assay 
and expressed as relative luminescence units (RLU = 
luciferase counts per milligram proteins). The 
orthotropic murine model of glioma was obtained, as 
described by Lo Dico et al [26], by stereotaxic injection 
of 1×105 U251-HRE-mCherry cells in 2 μl of phosphate 
buffered saline (PBS) into 7- to 8-week-old female 
nude mice (Harlan Laboratories, USA) at day 0. 
Following surgery, mice were monitored for recovery 
until complete awakening. 
Animals were grouped as follows: 
• Control group (scramble miRNA control, i.v.) 
• Mimic-treated group (i.v.) 
• Inhibitor-treated group (i.v.) 
For all studies, mice were injected every other 
day for a total of 4 administrations with 
1nmole/administration in 100µl of mixture of 
mimic/inhibitor or scramble. To make the mixture 
stable, the oligomers were injected by using a kit for 
delivering miRNA into animal tissue by systemic 
administration (AteloGene in vivo siRNA/miRNA 
Transfection kit, CosmoBio, DBA, Italy). After mixing 
miRNA mimic or scramble with Atelogene (1:1), the 
solution was slowly rotated at 4°C for 20 minutes. 
Then, samples were centrifuged at 10.000 rpm for 1 
minutes at 4°C to eliminate bubbles. For the 
mimic-study, the i.v. administration was performed 
between day 12 and day 18 after cell injection; for the 
inhibitor-study, the treatment was started at day 21 
and lasted until day 27. 
Optical imaging study design 
For the detection of bioluminescence or 
fluorescence, mice were i.p. anesthetized with Zoletil 
(40mg/kg, Virbac) and Xilor (8mg/kg, 
Sigma-Aldrich). The mice were then placed in the 
light-tight chamber and, 150 mg/kg of luciferin 
(Beetle Luciferin Potassium Salt, Promega) was 
intra-peritoneal injected in tumour-bearing mice for 
bioluminescence imaging (BLI). After biodistribution, 
bioluminescence was acquired [49]. The mCherry 
fluorescent signal was also measured by using the 
appropriate filters (excitation: 590-620 nm; 
emission=640-660 nm). HypoxiSense680 fluorescent 
probe (a CAIX-targeted fluorescent in vivo imaging 
agent, PerkinElmer Life Sciences) and IntegriSense750 
(targeting αvβ3 integrin, PerkinElmer Life Sciences) 
were i.v. administered to mice and, after 24h, 
fluorescence imaging (FLI) was performed, applying 
the specific filters (excitation: 625-655 nm and 
emission=690-710 nm; excitation: 695-725 nm and 
emission=770-790 nm, respectively). All BLI/FLI 
acquisitions were carried out with IVIS system 
(PerkinElmer Life Sciences); images were analysed 
and scaled after completion of all acquisitions, using 
the Living Image Software. The same region of 
interest (ROI) was applied on all bioluminescent or 
fluorescent tumours. Bioluminescence was expressed 
as average radiance (photons/second/square 
centimetre/steradian) which is a calibrated 
measurement of photon emission. Fluorescence was 
expressed as Average Radiant Efficiency 
(p/s/cm²/sr)/(µW/cm²), where the average radiance 
is further normalized for efficiency of excitation light. 
Mice were also submitted to 3D diffuse fluorescence 
imaging tomography (FLIT) for IntegriSense750 probe 
by supplementing acquisitions with an integrated CT 
scan.  
 
 
 
 
 
Figure 6. Time lines represent the schedule of i.v. administration for n=5 mice. Upper 
panel: mir675-5p mimic/scramble administration. Lower panel: miR675-5p 
inhibitor/scramble administration. 
 
Western Blotting 
SDS-PAGE and Western Blotting (WB) were 
performed according to standard protocols. Briefly, 
U251 cells after hypoxia treatment or transfection 
with miR675-5p inhibitor were lysed in lysis buffer 
containing 15mM Tris/ HCl pH7.5, 120mM NaCl, 
25mM KCl, 1mM EDTA, 0.5% Triton X100, Halt 
Protease Inhibitor Single-Use cocktail (100X, 
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ThermoScientifc). Whole lysates (15µg per lane) were 
separated using 4-12% NovexBis-Tris SDS-acrylamide 
gels (Invitrogen), electro-transferred on Nitrocellulose 
membranes (Bio-Rad), and immunoblotted with 
antibodies against the following proteins:, VHL (VHL 
(FL-181): sc-5575, Santa Cruz Biotechnology, INC.), 
HuR (HuR (3A2): sc-5261, Santa Cruz Biotechnology, 
INC.) and β-Actin (Monoclonal anti-β-actin, A5316 
Sigma). All secondary antibodies were obtained from 
Thermo Fisher Scientific. Immunofluorescence was 
detected using ChemiDoc Biorad acquisition 
instrument. 
RNA immunoprecipitation (RIP) 
In order to test the affinity of the RNA binding 
protein (RBP) HuR for HIF-1α and VEGF mRNAs, a 
RNA immunoprecipitation was performed, according 
to the manufacturer’s instructions (Imprint RNA 
Immunoprecipitation Kit, RIP-12RXN, 
Sigma-Aldrich). After RIP, RNA was identified by 
RT-PCR. Each RIP Ct value was normalized to the 
10% Input RNA fraction Ct value. Data were 
expressed as fold enrichment above the input 
percentage. 
Immunohistochemistry 
At the end of treatment, the animals were 
sacrificed and their brains were collected, fixed in 10% 
neutral buffered formalin (Sigma-Aldrich), 
dehydrated with increasing concentrations of ethanol 
(75, 85, 95 and 100%, 9 min each), xylene rinsed and 
finally paraffin-embedded. Longitudinal sections 
(3–4μm) were cut and stained with Haematoxylin and 
Eosin (H&E) for morphological evaluation and 
monoclonal anti-HIF-1α antibody (Novus Biological, 
CO) and anti-ki67 (Dako, CA, USA) according to the 
kit manufacturer's instructions.  
Statistical analysis 
In vitro experiments were repeated three times, 
giving reproducible results. Data are presented as 
mean values ± standard deviation (SD) of three 
independent experiments. For statistical analysis t-test 
or one- or two-way analysis of variance (ANOVA), 
followed by Dunnett’s or Bonferroni’s multiple 
comparison test, were performed using Prism 4 
(GraphPad SoftwareInc., CA, USA). 
Supplementary Material  
Supplementary figures.  
http://www.thno.org/v06p1105s1.pdf 
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